EMA Authorised: Xromi (hydroxycarbamide) — Lipomed GmbH

View source ↗

Summary

Xromi (hydroxycarbamide) has been authorised in the EU for use in anemia and sickle cell disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Sickle Cell Disease

Drugs mentioned

• XROMI (HYDROXYUREA)

Snippet

Status: Authorised. Therapeutic area: Anemia, Sickle Cell. MAH: Lipomed GmbH. Decision date: 07/04/2026